Bradon Heflin

Friendswood, TX – March 25, 2019 – Castle Biosciences, Inc., a cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced that it will present five-year outcomes from a prospective, multicenter study showing that DecisionDx®-UM accurately predicts metastatic risk for patients with uveal melanoma and is used by physicians to make …

Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test Read More »

Friendswood, TX – March 6, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of an independent, prospective study of patients with Stage IB and II cutaneous melanoma showing that the DecisionDx®-Melanoma gene expression profile (GEP) test accurately identifies risk of melanoma …

Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction Read More »

Friendswood, TX – March 4, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced three presentations at the 2019 American Academy of Dermatology (AAD) Annual Meeting held in Washington, DC from March 1-5. A meta-analysis of four DecisionDx®-Melanoma studies including 1,479 patients titled, “Meta-Analysis …

Meta-Analysis Showing DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk Presented during Late-Breaking Research Session at the 2019 AAD Annual Meeting Read More »

Friendswood, TX – February 7, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced the publication of a study highlighting the ability of the DecisionDx®-Melanoma test to accurately determine risk of metastasis in patients with melanoma of the head and neck. Results from …

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck Read More »

Friendswood, TX – January 30, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of data supporting clinical use of the DecisionDx®-Melanoma test to inform decisions for use of sentinel lymph node biopsy (SLNB), a surgical procedure used to help stage melanoma. …

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions Read More »

Friendswood, TX – January 7, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced a new publication demonstrating that the DecisionDx®-Melanoma gene expression profile (GEP) test can identify high-risk patients who are likely to recur or die from melanoma within groups of patients often …

Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study Read More »

Friendswood, TX – December 6, 2018 – Castle Biosciences, Inc., a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the appointment of G. Bradley Cole to its Board of Directors. Mr. Cole brings over 30 years of successful finance and operations leadership in the diagnostics and life sciences industries. …

Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to its Board of Directors Read More »

Friendswood, TX – November 21, 2018 – Castle Biosciences, Inc., a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced that Derek Maetzold, President and CEO, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28th, 2018 at 10:10 a.m. EST in New …

Castle Biosciences to Present at the 2018 Piper Jaffray Healthcare Conference Read More »

Friendswood, TX – Nov 13, 2018 – Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced study results showing that the DecisionDx-Melanoma test accurately predicts risk for patients with cutaneous melanoma when using either biopsy or wide local excision (WLE) as the tissue source. Highlights of …

Study Demonstrating Accuracy of DecisionDx-Melanoma Prognostic Test Across Melanoma Tissue Sources Presented at the American Society of Dermatopathology 55th Annual Meeting Read More »

Friendswood, TX – November 8, 2018 – Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced that Derek Maetzold, President and CEO, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15th, 2018 at 3:00 p.m. in New York City. About …

Castle Biosciences to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum Read More »